AsianScientist (Nov. 13, 2013) – Tokyo-based Eisai Co., Ltd. has entered into an agreement with the Broad Institute, a research facility that includes researchers from Harvard University and the Massachusetts Institute of Technology (MIT), to jointly discover and develop new therapeutic agents for the treatment of neglected tropical diseases (NTDs) and tuberculosis.
Eisai and the Broad Institute will collaborate to develop novel treatments for NTDs and tuberculosis through the optimization of compounds screened from Broad’s chemical library.
The first project is aimed at developing novel treatments for Chagas disease, an NTD. Chagas disease is transmitted by the bite of the assassin bug or vinchuca and particularly endemic in poorer areas of Latin America and the Caribbean.
The project has received partial funding by the Global Health Innovative Technology Fund (GHIT Fund), an international nonprofit organization.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.